Skip to main content

Table 3 Assumed HPV distributions for each model health state for the base case and sensitivity analyses

From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Health state HPV genotype Canadian data References Base case estimates † North America data Sensitivity analysis estimates‡ References
  16/18 24.9% [45] 24.9% 25.6% 22.0% [60]
CIN1 CP* 33.6%   33.6% 67.5% 57.0%  
  6/11 4.8%   4.8% 7.6% 6.0%  
  Other 6.9%   36.7% 17.8% 15.0%  
  16/18 56.2% [45] 56.2% 55.2% 50.0% [60]
CIN2/3 CP* 32.9%   32.9% 49.6% 45.0%  
  Other 2.5%   10.9% 5.6% 5.0%  
  16/18 74.3% [45] 74.3% 76.5% 85.0% [60]
Cancer CP* 18.3%   18.3% 13.6% 15.0%  
  Other 2.2%   7.4% 1.0% 0.0%  
Genital Warts 6/11   [61] 76.2%   76.2% [61]
  1. * CP: Cross-protection – oncogenic HPV types affected by the vaccine: HPV-31,-33,-35,-39,-45,-51,-52,-56,-58,-59.
  2. † The proportion in the other HPV category was increased as required so that all cervical outcomes were associated with an HPV infection.
  3. ‡ The sum of proportions of all HPV infections were equal to more than 100% for CIN1 and CIN2/3 lesions due to multiple HPV infections. For modelling purposes, the values in each HPV category were proportionally reduced so that sum of all HPV types equals 100% .
  4. CC – Cervical cancer.
  5. CIN – Cervical Intraepithelial Neoplasia.
  6. HPV – Human papillomavirus.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us